Literature DB >> 23679925

A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients.

Fabrizio Vincenzi1, Carmen Corciulo, Martina Targa, Ilaria Casetta, Mauro Gentile, Enrico Granieri, Pier Andrea Borea, Patrizia Popoli, Katia Varani.   

Abstract

Adenosine, a purine nucleoside interacting with A1, A2A, A2B and A3 adenosine receptors (ARs), is a potent endogenous modulator of inflammatory and neuronal processes involved in the pathophysiology of several neurodegenerative diseases. In the present study, ARs were investigated in lymphocytes from patients with amyotrophic lateral sclerosis (ALS) and compared with age-matched healthy subjects. In ALS patients A2AARs were analysed by using RT-PCR, Western blotting and saturation binding experiments. The effect of A2AAR stimulation on cyclic AMP levels was evaluated in lymphocytes from ALS patients and healthy subjects. An up-regulation of A2AARs was observed in ALS patients with respect to healthy subjects while A1, A2B and A3AR affinity and density did not change. In ALS patients, the A2AAR density values correlated with the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) scores. Furthermore, the stimulation of A2AARs mediated a significant increase in cyclic AMP levels in lymphocytes from ALS patients, with a higher potency than in lymphocytes from healthy subjects. In conclusion, the positive correlation between A2AAR density and ALSFRS-R scores could indicate a possible protective effect of this receptor subtype, representing an interesting starting point for the study of alternative therapeutic approaches for ALS based on A2AAR modulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23679925     DOI: 10.3109/21678421.2013.793358

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  13 in total

Review 1.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

2.  Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis.

Authors:  Seng Kah Ng; Haruki Higashimori; Michaela Tolman; Yongjie Yang
Journal:  Exp Neurol       Date:  2015-03-13       Impact factor: 5.330

3.  Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission.

Authors:  Filipe Nascimento; Ana M Sebastião; Joaquim A Ribeiro
Journal:  Purinergic Signal       Date:  2015-09-03       Impact factor: 3.765

4.  Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice.

Authors:  Monica Armida; Alessandra Matteucci; Antonella Pèzzola; Younis Baqi; Christa E Müller; Patrizia Popoli; Rosa Luisa Potenza
Journal:  Neurochem Res       Date:  2019-02-12       Impact factor: 3.996

Review 5.  Metabolic Aspects of Adenosine Functions in the Brain.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Maria Grazia Tozzi
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

6.  Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors.

Authors:  Sonja Hinz; Gemma Navarro; Dasiel Borroto-Escuela; Benjamin F Seibt; York-Christoph Ammon; Elisabetta de Filippo; Azeem Danish; Svenja K Lacher; Barbora Červinková; Muhammad Rafehi; Kjell Fuxe; Anke C Schiedel; Rafael Franco; Christa E Müller
Journal:  Oncotarget       Date:  2018-02-06

7.  Adenosine A2A Receptors Are Upregulated in Peripheral Blood Mononuclear Cells from Atrial Fibrillation Patients.

Authors:  Héctor Godoy-Marín; Romain Duroux; Kenneth A Jacobson; Concepció Soler; Hildegard Colino-Lage; Veronica Jiménez-Sábado; José Montiel; Leif Hove-Madsen; Francisco Ciruela
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

8.  Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase.

Authors:  Filipe Nascimento; Paula A Pousinha; Alexandra M Correia; Rui Gomes; Ana M Sebastião; Joaquim A Ribeiro
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

Review 9.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

Review 10.  Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors.

Authors:  Ana M Sebastião; Nádia Rei; Joaquim A Ribeiro
Journal:  Front Pharmacol       Date:  2018-04-16       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.